CL2012003071A1 - Un compuesto (4-cloro-piridin-3-il)-amida del acido 4-(2,2-difluoro-benzo[1,3]dioxol-5-ilmetil)-piperazina-1-carboxilico o su sal; metodo de sintesis; composicion farmaceutica, util para tratar un trastorno o afeccion mediado por la actividad de la faah tal como ansiedad, depresion, dolor, ulcera gastrica y esclerosis multiple. - Google Patents
Un compuesto (4-cloro-piridin-3-il)-amida del acido 4-(2,2-difluoro-benzo[1,3]dioxol-5-ilmetil)-piperazina-1-carboxilico o su sal; metodo de sintesis; composicion farmaceutica, util para tratar un trastorno o afeccion mediado por la actividad de la faah tal como ansiedad, depresion, dolor, ulcera gastrica y esclerosis multiple.Info
- Publication number
- CL2012003071A1 CL2012003071A1 CL2012003071A CL2012003071A CL2012003071A1 CL 2012003071 A1 CL2012003071 A1 CL 2012003071A1 CL 2012003071 A CL2012003071 A CL 2012003071A CL 2012003071 A CL2012003071 A CL 2012003071A CL 2012003071 A1 CL2012003071 A1 CL 2012003071A1
- Authority
- CL
- Chile
- Prior art keywords
- dioxol
- ylmethyl
- difluoro
- anxiety
- pyridin
- Prior art date
Links
- -1 4- (2,2-difluoro-benzo [1,3] dioxol-5-ylmethyl) -piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl) -amide compound Chemical class 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 208000007107 Stomach Ulcer Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 201000005917 gastric ulcer Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 101150042613 FA2H gene Proteins 0.000 title 1
- 101150008770 FAAH gene Proteins 0.000 title 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 abstract 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 abstract 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
Abstract
Un compuesto (4-cloro-piridin-3-il)-amida del ácido 4-(2,2-difluoro-benzo[1,3]dioxol-5-ilmetil)-piperazina-1-carboxílico o su sal; método de síntesis; composición farmacéutica, útil para tratar un trastorno o afección mediada por la actividad de la FAAH tal como ansiedad, depresión, dolor, úlcera gástrica y esclerosis múltiple.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33052210P | 2010-05-03 | 2010-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012003071A1 true CL2012003071A1 (es) | 2013-03-08 |
Family
ID=44080143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012003071A CL2012003071A1 (es) | 2010-05-03 | 2012-10-31 | Un compuesto (4-cloro-piridin-3-il)-amida del acido 4-(2,2-difluoro-benzo[1,3]dioxol-5-ilmetil)-piperazina-1-carboxilico o su sal; metodo de sintesis; composicion farmaceutica, util para tratar un trastorno o afeccion mediado por la actividad de la faah tal como ansiedad, depresion, dolor, ulcera gastrica y esclerosis multiple. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8940745B2 (es) |
| EP (1) | EP2566861B1 (es) |
| JP (1) | JP5841128B2 (es) |
| KR (1) | KR101770619B1 (es) |
| CN (1) | CN102869658B (es) |
| AU (1) | AU2011248407B2 (es) |
| BR (1) | BR112012028179A2 (es) |
| CA (1) | CA2797100C (es) |
| CL (1) | CL2012003071A1 (es) |
| DK (1) | DK2566861T3 (es) |
| EA (1) | EA022158B1 (es) |
| ES (1) | ES2483242T3 (es) |
| HR (1) | HRP20140724T1 (es) |
| IL (1) | IL222631A (es) |
| ME (1) | ME01912B (es) |
| MX (1) | MX2012012759A (es) |
| NZ (1) | NZ603175A (es) |
| PH (1) | PH12012502130A1 (es) |
| PL (1) | PL2566861T3 (es) |
| PT (1) | PT2566861E (es) |
| RS (1) | RS53376B (es) |
| SG (1) | SG185411A1 (es) |
| SI (1) | SI2566861T1 (es) |
| SM (1) | SMT201400067B (es) |
| UA (1) | UA108233C2 (es) |
| WO (1) | WO2011139951A1 (es) |
| ZA (1) | ZA201209042B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066747A1 (en) * | 2015-10-16 | 2017-04-20 | Scythian Biosciences Inc. | Methods and compositions for treating gastrointestinal inflammation |
| US20180303793A1 (en) * | 2015-10-16 | 2018-10-25 | Scythian Biosciences Inc. | Methods and compositions for treating traumatic brain injury |
| CN111743864B (zh) * | 2020-08-05 | 2022-04-01 | 牡丹江医学院 | 一种体育外伤喷雾剂及其制备方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4810160Y1 (es) | 1969-10-14 | 1973-03-16 | ||
| GB1292410A (en) | 1970-05-13 | 1972-10-11 | Yoshitomi Pharmaceutical | Thienobenzothiazepine derivatives |
| JPS5515456A (en) | 1978-07-19 | 1980-02-02 | Morishita Seiyaku Kk | 2-substituted-piperazinomethyl-1,4-benzodioxane |
| NZ223847A (en) | 1987-04-01 | 1989-12-21 | Janssen Pharmaceutica Nv | Substituted piperazine derivatives and pharmaceutical compositions |
| AU2000092A (en) | 1991-06-21 | 1993-01-25 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
| US5612380A (en) | 1994-09-27 | 1997-03-18 | The Scripps Research Institute | Method for sleep induction |
| CZ288002B6 (cs) | 1995-01-11 | 2001-03-14 | Samjin Pharmaceutical Co., Ltd. | Piperazinové deriváty a farmaceutický prostředek s protinádorovou aktivitou je obsahující |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| JP2000511949A (ja) | 1996-05-03 | 2000-09-12 | ワーナー―ランバート・コンパニー | ポリマー支持クェンチによる迅速精製 |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| US6124299A (en) | 1997-02-24 | 2000-09-26 | Zymogenetics, Inc. | Calcitonin mimetics |
| JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| HUP0102662A3 (en) | 1997-11-07 | 2003-01-28 | Schering Corp | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| JP2001523695A (ja) | 1997-11-24 | 2001-11-27 | ザ スクリップス リサーチ インスティテュート | ギャップ結合連絡の阻害剤 |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| NZ525108A (en) | 1998-03-31 | 2005-02-25 | Acadia Pharm Inc | Compounds with activity on muscarinic receptors |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| US6100279A (en) | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| AU1413301A (en) | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| US20020183316A1 (en) | 2000-10-27 | 2002-12-05 | Kevin Pan | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
| MXPA03009850A (es) | 2001-04-27 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso. |
| CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| WO2003047569A1 (en) | 2001-12-03 | 2003-06-12 | Gpc Biotech, Inc. | Compositions and methods for inhibiting prenyltransferases |
| US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| US6949574B2 (en) | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| BR0314980A (pt) | 2002-10-08 | 2005-08-09 | Scripps Research Inst | Inibidores de hidrolase de amida de ácido graxo |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US20040191155A1 (en) | 2003-03-25 | 2004-09-30 | Mahler Barry Asher | Thermal process for reducing the concentration of dinitrogen difluoride and dinitrogen tetrafluoride in nitrogen trifluoride |
| FR2854633B1 (fr) | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| DE602004013772D1 (de) | 2003-06-10 | 2008-06-26 | Janssen Pharmaceutica Nv | Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen |
| US7262020B2 (en) | 2003-07-03 | 2007-08-28 | The Regents Of The University Of California | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol |
| FR2864080B1 (fr) * | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| GB0503056D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| ITRM20060090A1 (it) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
| JP5026511B2 (ja) | 2006-05-18 | 2012-09-12 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシンａ２ｂレセプターアンタゴニストとしてのチアゾロ−ピラミジン／ピリジン尿素誘導体 |
| WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
| AU2008263166A1 (en) | 2007-05-25 | 2008-12-18 | Janssen Pharmaceutica N.V. | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| TW200924778A (en) | 2007-10-10 | 2009-06-16 | Takeda Pharmaceutical | Amide compound |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
-
2011
- 2011-02-05 UA UAA201213737A patent/UA108233C2/ru unknown
- 2011-05-02 BR BR112012028179A patent/BR112012028179A2/pt not_active Application Discontinuation
- 2011-05-02 US US13/695,855 patent/US8940745B2/en active Active
- 2011-05-02 ME MEP-2014-64A patent/ME01912B/me unknown
- 2011-05-02 RS RS20140319A patent/RS53376B/sr unknown
- 2011-05-02 CN CN201180022285.3A patent/CN102869658B/zh active Active
- 2011-05-02 AU AU2011248407A patent/AU2011248407B2/en active Active
- 2011-05-02 HR HRP20140724AT patent/HRP20140724T1/hr unknown
- 2011-05-02 NZ NZ603175A patent/NZ603175A/en not_active IP Right Cessation
- 2011-05-02 JP JP2013509137A patent/JP5841128B2/ja active Active
- 2011-05-02 SI SI201130191T patent/SI2566861T1/sl unknown
- 2011-05-02 WO PCT/US2011/034755 patent/WO2011139951A1/en not_active Ceased
- 2011-05-02 EP EP11719136.1A patent/EP2566861B1/en active Active
- 2011-05-02 PH PH1/2012/502130A patent/PH12012502130A1/en unknown
- 2011-05-02 DK DK11719136.1T patent/DK2566861T3/da active
- 2011-05-02 KR KR1020127031030A patent/KR101770619B1/ko active Active
- 2011-05-02 CA CA2797100A patent/CA2797100C/en active Active
- 2011-05-02 ES ES11719136.1T patent/ES2483242T3/es active Active
- 2011-05-02 EA EA201291155A patent/EA022158B1/ru unknown
- 2011-05-02 MX MX2012012759A patent/MX2012012759A/es active IP Right Grant
- 2011-05-02 SG SG2012081139A patent/SG185411A1/en unknown
- 2011-05-02 PL PL11719136T patent/PL2566861T3/pl unknown
- 2011-05-02 PT PT117191361T patent/PT2566861E/pt unknown
-
2012
- 2012-10-23 IL IL222631A patent/IL222631A/en active IP Right Grant
- 2012-10-31 CL CL2012003071A patent/CL2012003071A1/es unknown
- 2012-11-29 ZA ZA2012/09042A patent/ZA201209042B/en unknown
-
2014
- 2014-06-11 SM SM201400067T patent/SMT201400067B/xx unknown
- 2014-12-10 US US14/565,535 patent/US9688664B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA109547C2 (uk) | Композиція для боротьби з захворюванням рослин і спосіб боротьби з захворюванням рослин | |
| EA201291317A1 (ru) | Тетрагидропиридопиримидиновые производные | |
| MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| EA201070344A1 (ru) | 5-замещенные 2-(алкоксиметил)фураны | |
| UA116809C2 (uk) | Застосування агрохімічних сумішей для збільшення життєздатності рослини | |
| EA201391532A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| TN2013000362A1 (en) | Benzodioxane inhibitors of leukotriene production | |
| EA201500652A1 (ru) | Дифторметилникотиновые инданилкарбоксамиды | |
| UA108209C2 (uk) | Сполуки, які зв'язують фарнезоїдний х-рецептор (fxr,nr1h4) й модулюють його активність | |
| MY184015A (en) | Utilizing a multiphase reactor for the conversion of biomass to produce substituted furans | |
| MX355409B (es) | Proceso para la preparacion de n- [5- (3,5-difluoro-bencil) -1h-indazol-3-il] -4- (4-metil-piperazin-1-il) -2- (tetrahidro-piran-4-ilamino) -benzamida. | |
| MX340124B (es) | Anticuerpos biespecificos. | |
| IN2012DN05467A (es) | ||
| BR112012024133A2 (pt) | método para produzir 5-hidroximetilfurfural e para converter hmf, e, uso de ácido 2, 5-furanodicarboxílico | |
| EA201500574A1 (ru) | Новые инданилоксидигидробензофуранилуксусные кислоты | |
| BR112014016185A2 (pt) | processo para a produção de uma mistura de ácido 2,4-furandicarboxílico e ácido 2,5-furandicarboxílico (fdca) por meio de reação de dismutação, mistura de 2,4-fdca e 2,5-fdca obtenível por meio desta, 2,4-fdca obtenível por meio desta e uso de 2,4-fdca | |
| ITMI20081164A1 (it) | Processo per la produzione di esteri dell'acido levulinico da biomasse | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| IN2014MN01521A (es) | ||
| EA201190004A1 (ru) | Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3 | |
| FI20115328A0 (fi) | Uusia kutinaaseja, niiden tuottaminen ja käytöt | |
| CR20110107A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida (ms-275) | |
| CL2012003071A1 (es) | Un compuesto (4-cloro-piridin-3-il)-amida del acido 4-(2,2-difluoro-benzo[1,3]dioxol-5-ilmetil)-piperazina-1-carboxilico o su sal; metodo de sintesis; composicion farmaceutica, util para tratar un trastorno o afeccion mediado por la actividad de la faah tal como ansiedad, depresion, dolor, ulcera gastrica y esclerosis multiple. | |
| GEP20146196B (en) | Disubstituted tetrahydofuranyl compounds as antagonists of bradykinin b1 receptor | |
| EP2594274A4 (en) | NEW FACTOR FOR PROMOTING THE DECOMPOSITION OF HYALURONIC ACID AND HEMMER THEREOF |